Saturday, October 31, 2026

GBP/EUR Jumps By 1% In The Last 10 Sessions

GBP/EUR Jumps By 1% In The Last 10 Sessions

(VIANEWS) - GBP/EUR (GBPEUR) has been up by 1.15% for the last 10 sessions. At 03:08 EST on Thursday, 23 May, GBP/EUR (GBPEUR) is $1.18.

GBP/EUR's yearly highs and lows, it's 3.007% up from its 52-week low and 0.178% down from its 52-week high.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, GBP/EUR's Forex is considered to be oversold (<=20).

News about

  • According to FXStreet on Thursday, 23 May, "The USD/JPY pair could retest the upper boundary of the rising wedge near the psychological barrier at 157.00. ", "A break below this level could exert downward pressure on the USD/JPY pair, potentially moving it toward the throwback support at 151.86."
  • Usd/jpy price analysis: faces strong resistance as bulls target 157.00. According to FXStreet on Wednesday, 22 May, "The USD/JPY erased Tuesday's losses and climbed past the 156.50 area after the announcement of the latest US Federal Reserve meeting minutes. ", "The USD/JPY uptrend continues, yet it's facing stir resistance at the May 14 high of 156.76. "
  • According to FXStreet on Wednesday, 22 May, "The USD/JPY pair could retest the upper boundary of the ascending triangle near the psychological barrier at 157.00. ", "A break below this level could exert downward pressure on the USD/JPY pair, potentially moving it toward the throwback support at 153.60."

More news about GBP/EUR (GBPEUR).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com